<SEC-DOCUMENT>0001387131-16-005974.txt : 20160707
<SEC-HEADER>0001387131-16-005974.hdr.sgml : 20160707
<ACCEPTANCE-DATETIME>20160707170203
ACCESSION NUMBER:		0001387131-16-005974
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160707
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160707
DATE AS OF CHANGE:		20160707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		161757141

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_070716.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="text-transform: none">Washington,
D.C. 20549</FONT></P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-transform: uppercase; text-align: center">SECURITIES
EXCHANGE ACT OF 1934
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event
reported): July 7, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>TherapeuticsMD, Inc.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Exact Name of Registrant as Specified
in its Charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Jurisdiction of Incorporation)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">6800 Broken Sound Parkway NW,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Third Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Boca Raton, FL 33487</P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 40%; margin-top: 0; margin-bottom: 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding: 0; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Office) (Zip Code)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Registrant's telephone number, including area code: (561) 961-1900</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see</I> General Instruction A.2 below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-bottom: 12pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt"><B>Item 7.01</B></TD>
    <TD STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify; text-indent: 0.5in">TherapeuticsMD, Inc.
is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a press release issued on July 7, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The information in this Current Report on Form
8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be &ldquo;filed&rdquo;
for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
section, nor will any of such information or exhibits be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference
in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt"><B>Item&nbsp;9.01.</B></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt">(d)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><I>Exhibits.</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Exhibit</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Number</U></P></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-decoration: underline"><U>Description</U></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">99.1</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">Press Release from TherapeuticsMD, Inc. dated July 7, 2016, entitled &ldquo;TherapeuticsMD Announces New Drug Application Submission for Yuvvexy&trade; (TX-004HR).&rdquo; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; text-indent: 27.5pt">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">Date: July 7, 2016</TD>
    <TD COLSPAN="2">THERAPEUTICSMD, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 7%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 33%">/s/<I> Daniel A. Cartwright</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title:</P></TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Daniel A. Cartwright</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 1in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Exhibit</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Number</U></P></TD>
    <TD STYLE="vertical-align: bottom; text-decoration: underline"><U>Description</U></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;99.1</TD>
    <TD STYLE="vertical-align: bottom"><A HREF="ex99-1.htm">Press Release from TherapeuticsMD, Inc. dated July 7, 2016, entitled &ldquo;TherapeuticsMD Announces New Drug Application Submission for Yuvvexy&trade; (TX-004HR).&rdquo;</A> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>




<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 8pt; text-align: left"><A HREF="txmd-8k_070716.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 8pt; text-align: right"><B>Exhibit
99.1</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt 4in; text-align: right; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt 4in; text-align: right; text-indent: 0.5in"><IMG SRC="ex99-1_img001.jpg" ALT="" STYLE="height: 28px; width: 239px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>TherapeuticsMD Announces New
Drug Application Submission for Yuvvexy&trade; (TX-004HR)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><B>BOCA RATON, Fla., July 7, 2016</B>
&ndash; TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women&rsquo;s healthcare company, announced today that it has submitted
its New Drug Application (NDA) for Yuvvexy with the U.S. Food and Drug Administration (FDA). The NDA submission is supported by
the complete Yuvvexy clinical program, including positive results of the recently completed phase 3 Rejoice Trial. The NDA submission
includes all three doses of Yuvvexy (4 mcg, 10 mcg and 25 mcg) that were evaluated in the Rejoice Trial.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Yuvvexy, the conditionally-approved
trade name for the company&rsquo;s TX-004HR drug candidate, is an applicator-free, vaginal, estradiol softgel capsule being proposed
for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy
(VVA) due to menopause.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About TherapeuticsMD, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">TherapeuticsMD, Inc.&nbsp;is an
innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA&trade;
technology,&nbsp;TherapeuticsMD&nbsp;is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes. The company&rsquo;s clinical development pipeline includes
two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well
as over-the-counter vitamins under the vitaMedMD<SUP>&reg;</SUP> and BocaGreenMD<SUP>&reg;</SUP> brands.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><I>This press release by TherapeuticsMD,
Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating
to TherapeuticsMD&rsquo;s objectives, plans and strategies as well as statements, other than historical facts, that address activities,
events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These
statements are often characterized by terminology such as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;should,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;projects,&rdquo; &ldquo;positioned,&rdquo; &ldquo;strategy&rdquo; and similar expressions and are based on assumptions and
assessments made in light of management&rsquo;s experience and perception of historical trends, current conditions, expected future
developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the
date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of
new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject
to risks and uncertainties, many of which are outside of the company&rsquo;s control. Important factors that could cause actual
results, developments and business decisions to differ materially from forward-looking statements are described in the sections
titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s filings with the Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following:
the company&rsquo;s ability to maintain or increase sales of its products; the company&rsquo;s ability to develop and commercialize
its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the FDA will accept the company&rsquo;s
new drug application for its TX-004HR product candidate; the length, cost and uncertain results of the company&rsquo;s clinical
trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company&rsquo;s hormone
therapy drug candidates; the company&rsquo;s reliance on third parties to conduct its clinical trials, research and development
and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company&rsquo;s
products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility
of the trading price of the company&rsquo;s common stock and the concentration of power in its stock ownership. PDF copies of the
company&rsquo;s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"># # #</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Contact:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Investors</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">David Delucia</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Director of Investor Relations</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">561-961-1900</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">David.Delucia@TherapeuticsMD.com</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_img001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# D4# 2(  A$! Q$!_\0
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MI&940N[!549))P *Q_\ A+_#(./^$BTC_P #8_\ XJFDWL)M+=FS14<$\-S
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MX<^%M]:+M:=A&]Q(#G>_F)G'L.@_Q)JA\(NNL?\ ;'_V>NI^('_(CZE](_\
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M<=5&<X/5L'D5CAXMU%8WQ,DJ3OU-'X!_\S#_ -NW_M6O4?$W_(J:Q_UXS?\
MH!KR[X!_\S#_ -NW_M6O5=?@DNO#FIV\*EI9;25$4=R4( JJ_P#&^XG#_P !
M?/\ 4^<OA?\ \E(T?_?D_P#1;5]/5\L_#J[AL?B#HTT[%4,_EY]W4H/U85]3
M56+^-$8+X'ZA7C/Q\_YE[_MY_P#:5>S5XS\?/^9>_P"WG_VE6>'_ (B-,5_"
M9L_ W_D2;S_L(O\ ^BXZ\0GWP^)9/[2W.Z7A^TYZDA_F_K7M_P #?^1)O/\
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M2&W2QS0H6\E.I63J1M'\1X(YZY Q[;Q=XNG"65MK>K2O(P5$CG=G8]@,'=^
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M-2S']XIX KRK2!XPT'SO[,L-0@\[;YG^A%LXSC[RGU->[45M3K<D>6US@Q.
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
